ArticleJournal of medical genetics2005
A common variant of CDKN2A (p16) predisposes to breast cancer.
Article in Journal of medical genetics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 83 citations in OpenAlex.
- Senescence-associated and immune-related 9p21.3 locus genes in colorectal cancer: epigenetic architecture, molecular landscape and therapeutic possibilities.Frontiers in cell and developmental biology · 2026Review
- Prognosis of immunotherapy for non-small cell lung cancer withJournal of thoracic disease · 2024Article
- Article
- Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.International journal of molecular sciences · 2023Review
- Article
- Bladder cancer survival in patients withOncotarget · 2022Article
- BeyondJournal of clinical medicine · 2020Article
- The association between genetic variants in the genes for cytochrome P450 B1 and ATP-binding cassette transporter genes and breast cancer risk.Molecular biology reports · 2020Article
- Deficiency ofOncoTargets and therapy · 2020Article
- The association of a genetic variant in CDKN2A/B gene and the risk of colorectal cancer.EXCLI journal · 2020Article
- Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2020Article
- Association between polymorphism in CDKN2B-AS1 gene and its interaction with smoking on the risk of lung cancer in a Chinese population.Human genomics · 2019Article
- Obesity impacts the regulation of miR-10b and its targets in primary breast tumors.BMC cancer · 2019Article
- Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.JAMA oncology · 2019Article
- A genetic variant in CDKN2A/B gene is associated with the increased risk of breast cancer.Journal of clinical laboratory analysis · 2018Article
- Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population.Postepy dermatologii i alergologii · 2017Article
- Article
- Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Association between melanocytic nevi and risk of breast diseases: The French E3N prospective cohort.PLoS medicine · 2014Article
- Potential dual immunomodulatory role of VEGF in ulcerative colitis and colorectal carcinoma.International journal of medical sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA common missense variant of the CDKN2A gene (A148T) predisposes to malignant melanoma in Poland. An association between malignant melanoma and breast cancer has been reported in several families with CDKN2A mutations,
objectiveTo determine whether this variant also predisposes to breast cancer.
methodsGenotyping was undertaken in 4209 cases of breast cancer, unselected for family history, from 18 hospitals throughout Poland and in 3000 controls.
resultsThe odds ratio (OR) associated with the CDKN2A allele for women diagnosed with breast cancer before the age of 50 was 1.5 (p = 0.002) and after age 50 it was 1.3 (p = 0.2). The effect was particularly strong for patients diagnosed at or before the age of 30 (OR = 3.8; p = 0.0002).
conclusionsCDKN2A appears to be a low penetrance breast cancer susceptibility gene in Poland. The association should be confirmed in other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.